Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha (Q43039761)

12 November 2017

Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha (English)

1 reference

eradication of infectious diseases

12 November 2017

1 reference

1 reference

10

Jacques Izopet

1 reference

12 November 2017

2

Karine Sandres-Sauné

1 reference

12 November 2017

5

Martine Dubois

1 reference

12 November 2017

6

Christophe Pasquier

1 reference

12 November 2017

4

Laurent Alric

1 reference

12 November 2017

Anne Boulestin

1

1 reference

12 November 2017

Jean-Louis Payen

3

1 reference

12 November 2017

Jean-Pierre Vinel

7

1 reference

12 November 2017

Jean-Pierre Pascal

8

1 reference

12 November 2017

Jacqueline Puel

9

1 reference

12 November 2017

1 October 2002

1 reference

Journal of Medical Virology

12 November 2017

1 reference

12 November 2017

68

1 reference

12 November 2017

2

1 reference

12 November 2017

221-228

1 reference

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

12 November 2017

1 reference

The amino acid sequence of the PKR-eIF2alpha phosphorylation homology domain of hepatitis C virus envelope 2 protein and response to interferon-alpha

21 January 2018

1 reference

The scientific challenge of hepatitis C.

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

Quasispecies in viral persistence and pathogenesis of hepatitis C virus

21 January 2018

1 reference

Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

21 January 2018

1 reference

The treatment of chronic viral hepatitis

21 January 2018

1 reference

Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy

21 January 2018

1 reference

Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients

21 January 2018

1 reference

Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C.

21 January 2018

1 reference

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus

21 January 2018

1 reference

Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy

21 January 2018

1 reference

Nucleotide sequence and mutation rate of the H strain of hepatitis C virus

21 January 2018

1 reference

The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients

21 January 2018

1 reference

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

21 January 2018

1 reference

Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy

21 January 2018

1 reference

The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees

21 January 2018

1 reference

Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy

21 January 2018

1 reference

Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response

21 January 2018

1 reference

Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein

21 January 2018

1 reference

CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice

21 January 2018

1 reference

Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMV.10192

1 reference

12 November 2017

1 reference